Skip to main content
Erschienen in: Supportive Care in Cancer 6/2006

01.06.2006 | Original Article

Promulgation of guidelines for mucositis management: educating health care professionals and patients

verfasst von: Deborah B. McGuire, Judith Johnson, Cesar Migliorati

Erschienen in: Supportive Care in Cancer | Ausgabe 6/2006

Einloggen, um Zugang zu erhalten

Abstract

Background

The Multinational Association for Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) Mucositis and Patient and Professional Education Study Groups are collaborating to improve the promulgation of the updated mucositis management guidelines. The initial step in the collaboration was to survey cancer care health professionals to determine their awareness of the original 2004 guidelines and their opinions on the usefulness of patient educational materials based on the guidelines.

Materials and methods

The authors surveyed four samples (three US and one European) of cancer health care professionals attending three cancer-related professional conferences between May and July 2005 using a ten-item questionnaire in both paper-and-pencil and web-based formats. Data were compiled and analyzed using descriptive statistics.

Results

All respondents were generally aware of the importance of mucositis as a treatment-limiting toxicity with life-threatening complications and endorsed regular oral assessment and dental care practices. Only about one third of the US respondents were aware of the 2004 guidelines in contrast to 80% of the European respondents. A majority of respondents across all four surveys (66–93%) felt strongly that educational materials based on the guidelines were needed and that they would use them, while a smaller number (7–29%) indicated they might use them if a patient had a problem with mucositis.

Conclusions

Awareness of the guidelines remains limited in the US, and use of the guidelines worldwide is minimal. The Mucositis and Patient and Professional Education Study Groups have developed a set of strategies to enhance dissemination, awareness, and use of the updated guidelines and to promote patient education based on the guidelines. Future work will focus on implementation and evaluation of the guidelines in clinical practice.
Literatur
2.
Zurück zum Zitat Arnold R et al (1991) Educating for a change. Doris Marshall Institute for Education and Action, Toronto (Ontario, Canada), Between the Lines, Toronto, Ontario, Canada Arnold R et al (1991) Educating for a change. Doris Marshall Institute for Education and Action, Toronto (Ontario, Canada), Between the Lines, Toronto, Ontario, Canada
3.
Zurück zum Zitat Barker GJ, Epstein JB, Williams KB, Gorsky M, Raber-Durlacher JE (2005) Current practice and knowledge of oral care for cancer patients: a survey of supportive health care providers. Support Care Cancer 13:32–41PubMedCrossRef Barker GJ, Epstein JB, Williams KB, Gorsky M, Raber-Durlacher JE (2005) Current practice and knowledge of oral care for cancer patients: a survey of supportive health care providers. Support Care Cancer 13:32–41PubMedCrossRef
4.
Zurück zum Zitat Cooley ME, Moriarty H, Berger MS, SElm-Orr D, Coyle B, Short T (1995) Patient literacy and the readability of written cancer educational materials. Oncol Nurs Forum 22:1345–1351PubMed Cooley ME, Moriarty H, Berger MS, SElm-Orr D, Coyle B, Short T (1995) Patient literacy and the readability of written cancer educational materials. Oncol Nurs Forum 22:1345–1351PubMed
5.
Zurück zum Zitat Daniel BT, Damato KL, Johnson J (2004) Educational issues in oral care. Semin Oncol Nurs 20:48–52PubMedCrossRef Daniel BT, Damato KL, Johnson J (2004) Educational issues in oral care. Semin Oncol Nurs 20:48–52PubMedCrossRef
6.
Zurück zum Zitat Doak LG, Doak CC, Meade CD (1996) Strategies to improve cancer education materials. Oncol Nurs Forum 23:1305–1312PubMed Doak LG, Doak CC, Meade CD (1996) Strategies to improve cancer education materials. Oncol Nurs Forum 23:1305–1312PubMed
7.
Zurück zum Zitat Fulton JF, Middleton GJ, McPhail JT (2002) Management of oral complications. Semin Oncol Nurs 18:28–35PubMedCrossRef Fulton JF, Middleton GJ, McPhail JT (2002) Management of oral complications. Semin Oncol Nurs 18:28–35PubMedCrossRef
8.
Zurück zum Zitat McGuire DB (2003) Barriers and strategies in implementation of oral care standards for cancer patients. Support Care Cancer 11:435–441PubMedCrossRef McGuire DB (2003) Barriers and strategies in implementation of oral care standards for cancer patients. Support Care Cancer 11:435–441PubMedCrossRef
9.
Zurück zum Zitat McGuire D, Johnson J (2005) Developing an educational resource for mucositis: using the MASCC/ISOO mucositis guidelines in planning health professional and patient education in clinical practice. Symposium presentation (mucositis guidelines update), MASCC-ISOO 17th annual meeting, Geneva, Switzerland, 2005. http://www.mascc.org (Mucositis Resource Center, Education section) McGuire D, Johnson J (2005) Developing an educational resource for mucositis: using the MASCC/ISOO mucositis guidelines in planning health professional and patient education in clinical practice. Symposium presentation (mucositis guidelines update), MASCC-ISOO 17th annual meeting, Geneva, Switzerland, 2005. http://​www.​mascc.​org (Mucositis Resource Center, Education section)
10.
Zurück zum Zitat McGuire DB, Peterson DE, Rubenstein E (2004) Evidence-based guidelines for managing mucositis. Semin Oncol Nurs 20:59–66PubMedCrossRef McGuire DB, Peterson DE, Rubenstein E (2004) Evidence-based guidelines for managing mucositis. Semin Oncol Nurs 20:59–66PubMedCrossRef
11.
Zurück zum Zitat Melnyk BM, Fineout-Overholt E (2005) Making the case for evidence-based practice. In: Melnyk BM, Fineout-Overholt E (eds) Evidence-based practice in nursing and healthcare: a guide to best practice. Lippincott Williams & Wilkins, Philadelphia, pp 3–24 Melnyk BM, Fineout-Overholt E (2005) Making the case for evidence-based practice. In: Melnyk BM, Fineout-Overholt E (eds) Evidence-based practice in nursing and healthcare: a guide to best practice. Lippincott Williams & Wilkins, Philadelphia, pp 3–24
12.
Zurück zum Zitat Merriam-Webster’s Collegiate Dictionary, 11th edn. Merriam-Webster, Springfield, MA Merriam-Webster’s Collegiate Dictionary, 11th edn. Merriam-Webster, Springfield, MA
13.
Zurück zum Zitat Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, Elting LS, Fox PC, Cooksley C, Sonis ST (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100(9):2026–2046 (Suppl)PubMedCrossRef Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, Elting LS, Fox PC, Cooksley C, Sonis ST (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100(9):2026–2046 (Suppl)PubMedCrossRef
14.
Zurück zum Zitat Sadler GR, Oberlee-Edwards L, Farooqi A, Hryniuk WM (2000) Oral sequelae of chemotherapy: an important teaching opportunity for oncology health care providers and their patients. Support Care Cancer 8:209–214PubMedCrossRef Sadler GR, Oberlee-Edwards L, Farooqi A, Hryniuk WM (2000) Oral sequelae of chemotherapy: an important teaching opportunity for oncology health care providers and their patients. Support Care Cancer 8:209–214PubMedCrossRef
Metadaten
Titel
Promulgation of guidelines for mucositis management: educating health care professionals and patients
verfasst von
Deborah B. McGuire
Judith Johnson
Cesar Migliorati
Publikationsdatum
01.06.2006
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 6/2006
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-006-0060-7

Weitere Artikel der Ausgabe 6/2006

Supportive Care in Cancer 6/2006 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.